Clinical Trial Studies — Contract With Customer Liability Revenue Recognized

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ2 2021

Last reportedQ2 2021Aug 6, 2021

Rolls up toContract With Customer Liability Revenue Recognized

How to read this metric

An increase indicates higher project execution and milestone achievement within clinical trial partnerships, while a decrease may suggest project delays or a slowdown in new contract intake.

Detailed definition

This metric represents the portion of deferred revenue related to clinical trial service contracts that has been recogni...

Peer comparison

Comparable to 'Revenue from Contract Liabilities' or 'Recognized Deferred Revenue' in other life sciences or contract research organizations (CROs) that provide specialized diagnostic services.

Metric ID: ntra_segment_clinical_trial_studies_contract_with_customer_liability_revenue_recognized

Historical Data

1 periods

	Q2 '21
Value	$0

Similar Metrics at Other Companies

ModernaMRNA View metric

Nasdaq, Inc.NDAQ View metric

Okta, Inc.OKTA View metric

Nasdaq, Inc.NDAQ View metric

Frequently Asked Questions

What is Natera, Inc.'s clinical trial studies — contract with customer liability revenue recognized?: Natera, Inc. (NTRA) reported clinical trial studies — contract with customer liability revenue recognized of $0 in Q2 2021.
What does clinical trial studies — contract with customer liability revenue recognized mean?: The amount of revenue recognized during the period from clinical trial service contracts that were previously recorded as liabilities.